for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

34.91USD

Change

0.63(+1.84%)

Volume

6,448,427

Today's Range

34.33

 - 

34.97

52 Week Range

31.43

 - 

43.18

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
34.28
Open
34.36
Volume
6,448,427
3M AVG Volume
114.39
Today's High
34.97
Today's Low
34.33
52 Week High
43.18
52 Week Low
31.43
Shares Out (MIL)
5,031.02
Market Cap (MIL)
86,556.60
Forward P/E
12.08
Dividend (Yield %)
6.05

Next Event

GlaxoSmithKline PLC at Barclays Global Healthcare Conference (Virtual)

Latest Developments

More

Morphosys Says Licensing Partner GSK Shared Prelim Results From OSCAR Study With Otilimab

EMA Says CHMP Endorses GSK's Dostarlimab For Treatment Of Advanced Endometrial Cancer

Dodge & Cox Discloses 5.04% Stake In GSK As Of Feb. 19 - Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Major Drugs

Contact Info

G S K House, 980 Great West Road

TW8 9GS

United Kingdom

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

41.1K

2019

43.1K

2020

43.7K

2021(E)

48.3K
EPS (USD)

2018

3.104

2019

3.161

2020

2.973

2021(E)

2.890
Price To Earnings (TTM)
10.98
Price To Sales (TTM)
1.83
Price To Book (MRQ)
4.33
Price To Cash Flow (TTM)
9.42
Total Debt To Equity (MRQ)
186.12
LT Debt To Equity (MRQ)
160.59
Return on Investment (TTM)
12.68
Return on Equity (TTM)
7.98

Latest News

Latest News

GSK narrows focus on elderly in trial to treat pneumonia from COVID-19

GlaxoSmithKline will extend a trial testing an experimental rheumatoid arthritis drug on patients suffering from pneumonia related to COVID-19 to focus on the elderly as it seeks to firm up encouraging findings so far.

BRIEF-Dodge & Cox Discloses 5.04% Stake In GSK As Of Feb. 19 - Filing

* DODGE & COX DISCLOSES 5.04% STAKE IN GSK AS OF FEB. 19 - FILING Source text for Eikon: Further company coverage:

Federal Circuit panel to rehear Teva's 'skinny label' appeal

A Federal Circuit U.S. Court of Appeals panel agreed Tuesday hear new arguments on its October decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though Teva's drug came with a so-called...

GSK and Sanofi start with new COVID-19 vaccine study after setback

GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch.

BRIEF-GSK Announces New Gender And Diversity Aspirational Targets

* GSK - THE COMPANY WILL NOW EXTEND TARGET TO INCREASE FEMALE REPRESENTATION IN VP LEVEL AND ABOVE ROLES TO AT LEAST 45% BY 2025

BRIEF-GSK, On Sandoz Deal, Says Proposes To Close Cephalosporins Manufacturing Ops

* GSK, ON SANDOZ DEAL, SAYS PROPOSES TO CLOSE ITS CEPHALOSPORINS MANUFACTURING OPERATIONS ONCE TRANSFER OF MANUFACTURING OPERATIONS TO SANDOZ IS COMPLETE

UPDATE 1-Novartis buys antibiotics business from GSK in generics push

Swiss drugmaker Novartis' generics division is buying a GlaxoSmithKline antibiotics business that includes the brands Zinnat, Zinacef and Fortum for up to $500 million, the drugmakers said on Thursday.

Full Federal Circuit to hear Teva's 'skinny label' appeal

The full Federal Circuit U.S. Court of Appeals agreed Tuesday to a review of an October panel decision that Teva Pharmaceutical Industries Ltd's generic version of GlaxoSmithKline PLC's heart drug Coreg infringed a GSK patent, even though Teva's drug came with a so-called...

GSK, CureVac team up to develop vaccine against COVID-19 variants

Britain's GlaxoSmithKline and German biotech firm CureVac have teamed up in a 150 million euro ($180 million) deal to develop a COVID-19 vaccine from next year that could target several variants with one shot.

BRIEF-GlaxoSmithKline, CureVac Partner On Next-Generation Covid-19 Vaccines

* CO, CUREVAC N.V. TODAY ANNOUNCED A NEW EUR 150M COLLABORATION

China's Clover ends COVID-19 vaccine partnership with GSK

China's Clover Biopharmaceuticals said on Monday it has terminated its partnership with GlaxoSmithKline Plc (GSK) to develop a COVID-19 vaccine using the British drug maker's adjuvant.

UPDATE 1-Eli Lilly testing COVID-19 antibody treatment with Vir Biotech's drug

Eli Lilly and Co is testing its COVID-19 antibody therapy in combination with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline , in an effort to combat new variants of the coronavirus.

Eli Lilly to test COVID-19 antibody treatment with Vir Biotech's drug

Eli Lilly and Co said on Wednesday it would test a combination of its COVID-19 antibody therapy with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline.

BRIEF-GSK, Lilly, Vir Collaborate To Evaluate Combined COVID-19 Therapy

* LILLY, VIR BIOTECHNOLOGY AND GSK ANNOUNCE FIRST PATIENT DOSED IN EXPANDED BLAZE-4 TRIAL EVALUATING BAMLANIVIMAB (LY-COV555) WITH VIR-7831 (GSK4182136) FOR COVID-19

Sanofi confirms its will supply over 125 million Pfizer-BioNTech doses to the EU

French pharmaceutical giant Sanofi said on Wednesday it had struck an agreement with Germany's BioNTech to supply the European Union with the company's vaccine developed in partnership with U.S. group Pfizer.

U.S. FDA approves GSK unit's long-acting HIV injection

The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare.

Merck KGaA, GSK suffer lung cancer drug setback

Merck KGaA's drug development programme has suffered a setback with its most important experimental drug, cancer treatment bintrafusp alfa, failing early in its lead trial.

Merck KGaA stops lung cancer trial testing drug hopeful bintrafusp alfa

Germany's Merck KGaA said the most important clinical trial testing its cancer drug hopeful bintrafusp alfa, which it is co-developing with GlaxoSmithKline, would be stopped because the treatment does not appear to work.

FDA rejects GSK's request to weigh in on Zofran birth defect litigation

The U.S. Food and Drug Administration has rejected GlaxoSmithKline's request to weigh in on a key question in lawsuits by women who say the drugmaker failed to warn them that taking the anti-nausea drug Zofran during pregnancy can cause birth defects.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up